Fallopian Tube Cancer Clinical Trials

62 recruitingLast updated: June 17, 2026

There are 62 actively recruiting fallopian tube cancer clinical trials across 43 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include New York, New York, United States, Houston, Texas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Fallopian Tube Cancer Trials at a Glance

62 actively recruiting trials for fallopian tube cancer are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 31 trials, with the heaviest enrollment activity in New York, Houston, and Boston. Lead sponsors running fallopian tube cancer studies include AbbVie, M.D. Anderson Cancer Center, and Regeneron Pharmaceuticals.

Browse fallopian tube cancer trials by phase

Treatments under study

About Fallopian Tube Cancer Clinical Trials

Looking for clinical trials for Fallopian Tube Cancer? There are currently 48 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fallopian Tube Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fallopian Tube Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled66 locationsNCT06890338
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled172 locationsNCT06824467
Recruiting
Phase 1

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver50 enrolled2 locationsNCT06856499
Recruiting
Phase 2

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube CancerOvary CancerPeritoneal Cancer
University of Colorado, Denver53 enrolled5 locationsNCT05887609
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

Ovarian CancerCervical CancerEndometrial Cancer+5 more
Aesculap AG132 enrolled2 locationsNCT06024109
Recruiting
Phase 1Phase 2

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting
Phase 2

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Gynecologic CancersFallopian Tube CancerPlatinum-sensitive Ovarian Cancer+1 more
AbbVie377 enrolled16 locationsNCT07024784
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Primary Peritoneal CancerFallopian Tube CancersAdvanced High-Grade Epithelial Ovarian Cancer
AbbVie110 enrolled52 locationsNCT06682988
Recruiting
Phase 1

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian CancerFallopian Tube CancerPrimary Peritoneal
AstraZeneca24 enrolled9 locationsNCT07402915
Recruiting
Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled52 locationsNCT06787612
Recruiting
Phase 1

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer

Peritoneal CarcinomatosisMetastatic Ovarian CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+4 more
Hospices Civils de Lyon15 enrolled6 locationsNCT04811703
Recruiting
Phase 1

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Ovarian CancerFallopian Tube CancerOvarian Cancer Stage III+4 more
Brigham and Women's Hospital20 enrolled2 locationsNCT04701645
Recruiting
Not Applicable

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Ovarian CancerOvarian CarcinomaPrimary Peritoneal Carcinoma+11 more
Memorial Sloan Kettering Cancer Center35 enrolled7 locationsNCT05429970
Recruiting
Phase 2

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

Breast CancerGynecologic CancersOvarian Cancer+7 more
Peking University People's Hospital220 enrolled1 locationNCT07586826
Recruiting
Phase 1Phase 2

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 3

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled59 locationsNCT05659381
Recruiting
Phase 3

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.384 enrolled1 locationNCT06994195